160 related articles for article (PubMed ID: 15172086)
61. Effects of tibolone on body composition in postmenopausal women: a 1-year follow up study.
Boyanov MA; Shinkov AD
Maturitas; 2005 Aug; 51(4):363-9. PubMed ID: 16039409
[TBL] [Abstract][Full Text] [Related]
62. Short-term effects of hormone therapy on serum C-reactive protein levels in postmenopausal women.
Kiran H; Kiran G
Arch Gynecol Obstet; 2006 Apr; 274(1):9-12. PubMed ID: 16369811
[TBL] [Abstract][Full Text] [Related]
63. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
[TBL] [Abstract][Full Text] [Related]
64. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene.
Tommaselli GA; Di Carlo C; Di Spiezio Sardo A; Bifulco G; Cirillo D; Guida M; Capasso R; Nappi C
Menopause; 2006; 13(4):660-8. PubMed ID: 16837888
[TBL] [Abstract][Full Text] [Related]
65. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
Hudita D; Posea C; Ceausu I; Rusu M
Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
[TBL] [Abstract][Full Text] [Related]
66. Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study.
Rattanachaiyanont M; Angsuwathana S; Techatrisak K; Tanmahasamut P; Indhavivadhana S; Leerasiri P
J Obstet Gynaecol Res; 2005 Apr; 31(2):98-106. PubMed ID: 15771634
[TBL] [Abstract][Full Text] [Related]
67. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
[TBL] [Abstract][Full Text] [Related]
68. Effect of a long acting GnRH analogue or placebo on plasma LH/FSH, urethral pressure profiles and clinical signs of urinary incontinence due to Sphincter mechanism incompetence in bitches.
Reichler IM; Jöchle W; Piché CA; Roos M; Arnold S
Theriogenology; 2006 Sep; 66(5):1227-36. PubMed ID: 16672159
[TBL] [Abstract][Full Text] [Related]
69. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
[TBL] [Abstract][Full Text] [Related]
70. [Is the clinical profile of women treated with tibolone similar to that of women receiving a classical estrogen-progestogen therapy? Data from a nationwide survey in France].
Jamin C; Bourg F; Legeai J; Senoussi S
Gynecol Obstet Fertil; 2006 Mar; 34(3):224-32. PubMed ID: 16513401
[TBL] [Abstract][Full Text] [Related]
71. Low-dose add-back therapy during postoperative GnRH agonist treatment.
Tsai HW; Wang PH; Huang BS; Twu NF; Yen MS; Chen YJ
Taiwan J Obstet Gynecol; 2016 Feb; 55(1):55-9. PubMed ID: 26927249
[TBL] [Abstract][Full Text] [Related]
72. Tibolone low dose (1.25 mg/d) therapy and postural balance in elderly women.
Naessen T; Lindmark B; Larsen HC; van Os S; Larsson M
Maturitas; 2009 Jan; 62(1):72-5. PubMed ID: 19097714
[TBL] [Abstract][Full Text] [Related]
73. Carcinoma of the endometrium in patients treated with tibolone.
Yazigi R; Sahid S; Contreras L; Rodriguez T
Gynecol Oncol; 2004 May; 93(2):568-70. PubMed ID: 15099984
[TBL] [Abstract][Full Text] [Related]
74. Current approaches to optimizing the treatment of endometriosis in adolescents.
Laufer MR
Gynecol Obstet Invest; 2008; 66 Suppl 1():19-27. PubMed ID: 18936548
[TBL] [Abstract][Full Text] [Related]
75. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain.
Bedaiwy MA; Casper RF
Fertil Steril; 2006 Jul; 86(1):220-2. PubMed ID: 16716325
[TBL] [Abstract][Full Text] [Related]
76. [The influence of a tibolone therapy on endometrium in postmenopausal women].
Szlendak-Sauer K; Wierzba W; Radowicki S
Ginekol Pol; 2008 Nov; 79(11):758-61. PubMed ID: 19140498
[TBL] [Abstract][Full Text] [Related]
77. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.
Mitwally MF; Gotlieb L; Casper RF
Menopause; 2002; 9(4):236-41. PubMed ID: 12082359
[TBL] [Abstract][Full Text] [Related]
78. [Bone loss induced by GnRH agonist treatment].
Onoe Y; Ohta H
Nihon Rinsho; 2004 Feb; 62 Suppl 2():702-5. PubMed ID: 15035212
[No Abstract] [Full Text] [Related]
79. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.
Surrey ES; Hornstein MD
Obstet Gynecol; 2002 May; 99(5 Pt 1):709-19. PubMed ID: 11978277
[TBL] [Abstract][Full Text] [Related]
80. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study.
Grimbizis G; Tsalikis T; Tzioufa V; Kasapis M; Mantalenakis S
Hum Reprod; 1999 Feb; 14(2):479-84. PubMed ID: 10099998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
